Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)
PHASE1CompletedINTERVENTIONAL
Enrollment
23
Participants
Timeline
Start Date
November 14, 2013
Primary Completion Date
September 1, 2014
Study Completion Date
September 8, 2014
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG
MK-8892
DRUG
Placebo for MK-8892
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01926509 - Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) | Biotech Hunter | Biotech Hunter